Searchable abstracts of presentations at key conferences in endocrinology

ea0086oc1.6 | Bone and Calcium | SFEBES2022

The AXT914 calcilytic compound increases plasma calcium and PTH in a mouse model for autosomal dominant hypocalcaemia type 1 (ADH1)

Kooblall Kreepa , Hannan Fadil , Stevenson Mark , Lines Kate , Meng Xin , Stewart Michelle , Wells Sara , Gasser Jurg , Thakker Rajesh

Heterozygous germline gain-of-function mutations of the extracellular calcium-sensing receptor (CaSR), a G-protein coupled receptor (GPCR), result in autosomal dominant hypocalcaemia type 1 (ADH1), which may cause symptomatic hypocalcaemia with low circulating parathyroid hormone (PTH) concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, rectify the gain-of-function caused by CaSR mutations and are a potential targeted therapy for ADH1....